Inhibition of prostate cancer by suicide gene targeting the FCY1 and HSV-TK genes

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1341-1347

  Yue, Qiao Hong ^a   Hu, Xing Bin ^a   Yin, Ying ^b   Su, Ming Quan ^a   Cheng, Xiao Dong ^a   Yang, Liu ^a   Zhou, Tie Cheng ^a   Hao, Xiaoke ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Androgen signal; Double suicide gene; Prostate cancer; PSMA promoter

Indexed keywords

FLUCYTOSINE; GANCICLOVIR; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; GENE ACTIVATION; GENE CONSTRUCT; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HISTOPATHOLOGY; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN TARGETING; SUICIDE GENE; TUMOR GROWTH; TUMOR VOLUME;

CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HELA CELLS; HUMANS; MALE; MODELS, GENETIC; NEOPLASM METASTASIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; TETRAZOLIUM SALTS; THIAZOLES; THYMIDINE KINASE; TREATMENT OUTCOME;

EID: 70449336317     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000573     Document Type: Article

References (34)

1. Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH, Schmidlin F, Miralbell R and Zanetti R: Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 123: 421-429, 2008.
2. Li XM, Li J, Tsuji I, Nakaya N, Nishino Y and Zhao XJ: Mass screening-based case-control study of diet and prostate cancer in Changchun, China. Asian J Androl 10: 551-560, 2008.
3. Dieli F, Caccamo N and Meraviglia S: Advances in immunotherapy of castration-resistant prostate cancer: Bisphosphonates, phosphoantigens and more. Curr Opin Investig Drugs 9: 1089-1094, 2008.
4. Damber JE and Aus G: Prostate cancer. Lancet 371: 1710-1721, 2008.
5. Hao XK, Liu JY, Yue QH, Wu GJ, Bai YJ and Yin Y: In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein. Prostate 66: 858-866, 2006.
6. McPhaul MJ: Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab 22: 373-388, 2008.
7. Schroder FH: Progress in understanding androgen-independent prostate cancer (AIPC): A review of potential endocrine-mediated mechanisms. Eur Urol 53: 1129-1137, 2008.
8. Navarro D, Luzardo OP, Fernandez L, Chesa N and Diaz-Chico BN: Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 81: 191-201, 2002.
9. Uchida K, Masumori N, Takahashi A, Itoh N, Kato K, Matusik RJ and Tsukamoto T: Murine androgen-independent neuroendocrine carcinoma promotes metastasis of human prostate cancer cell line lncap. Prostate 66: 536-545, 2006.
10. Altaner C: Prodrug cancer gene therapy. Cancer Lett 270: 191-201, 2008.
11. Hamstra DA, Lee KC, Tychewicz JM, Schepkin VD, Moffat BA, Chen M, Dornfeld KJ, Lawrence TS, Chenevert TL, Ross BD, Gelovani JT and Rehemtulla A: The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther 10: 916-928, 2004.
12. Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ, Harris PA, Mountain A and Wrighton CJ: Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors. Mol Ther 3: 233-240, 2001.
13. Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, Martin J, Lehouritis P, Marais R and Springer CJ: Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT. J Med Chem 46: 1690-1705, 2003.
14. Marples B, Greco O, Joiner MC and Scott SD: Molecular approaches to chemo-radiotherapy. Eur J Cancer 38: 231-239, 2002.
15. Patterson AV, Saunders MP and Greco O: Prodrugs in genetic chemoradiotherapy. Curr Pharm Des 9: 2131-2154, 2003.
16. Khatri A, Zhang B, Doherty E, Chapman J, Ow K, Pwint H, Martiniello-Wilks R and Russell PJ: Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med 8: 1086-1096, 2006.
17. Mallano A, Zamboni S, Carpinelli G, Santoro F, Flego M, Ascione A, Gellini M, Tombesi M, Podo F and Cianfriglia M: Generation and characterization of a human single-chain fragment variable (scFv) antibody against cytosine deaminase from yeast. BMC Biotechnol 8: 68, 2008.
18. Martiniello-Wilks R, Dane A, Voeks DJ, Jeyakumar G, Mortensen E, Shaw JM, Wang XY, Both GW and Russell PJ: Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 6: 43-54, 2004.
19. Zeng H, Wei Q, Huang R, Chen N, Dong Q, Yang Y and Zhou Q: Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/ promoter. J Androl 28: 827-835, 2007.
20. Khatri A and Russell PJ: Targeted, gene-directed enzyme prodrug therapies to tackle diversity and aggression of late stage prostate cancer. Discov Med 7: 39-45, 2007.
21. Kusumi T, Koie T, Tanaka M, Matsumoto K, Sato F, Kusumi A, Ohyama C and Kijima H: Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathol Int 58: 687-694, 2008.
22. + lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. Prostate 68: 1-10, 2008.
23. Doehn C, Bohmer T, Kausch I, Sommerauer M and Jocham D: Prostate cancer vaccines: Current status and future potential. BioDrugs 22: 71-84, 2008.
24. Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH and Kao C: Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clin Cancer Res 14: 291-299, 2008.
25. Yue Q, Hu X, Yin W, Xu X, Wei S, Lei Y, Lu X, Yang J, Su M, Xu Z and Hao X: Immune responses to recombinant mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice. J Virol Methods 141: 41-48, 2007.
26. Wang XY, Martiniello-Wilks R, Shaw JM, Ho T, Coulston N, Cooke-Yarborough C, Molloy PL, Cameron F, Moghaddam M, Lockett TJ, Webster LK, Smith IK, Both GW and Russell PJ: Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther 11: 1559-1567, 2004.
27. Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridyland J, Simko J, Carroll PR, Rubin MA and Collins C: Genomic profiling of hormone-naive lymph node metastases in patients with prostate cancer. Neoplasia 8: 1083-1089, 2006.
28. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF and Moriarty R: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326-334, 1996.
29. Douglas TH, Morgan TO, McLeod DG, Moul JW, Murphy GP and Barren R III, Sesterhenn IA and Mostofi FK: Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. Cancer 80: 107-114, 1997.
30. Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley EL and Siegert G: Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: Regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia 10: 279-286, 2008.
31. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC and Rees RC: DNA demethylation and histone deacetylation inhibition cooperate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 68: 210-222, 2008.
32. Ikegami S, Tadakuma T, Ono T, Suzuki S, Yoshimura I, Asano T and Hayakawa M: Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci 95: 367-370, 2004.
33. Ci M, Mayumi Y, Andre B, Pascal B, Lin G, Yasukazu T, Fernand L and St-Amand J: Prostate-specific genes and their regulation by dihydrotestosterone. Prostate 68: 241-254, 2008.
34. Loberg RD, Day LL, Dunn R, Kalikin LM and Pienta KJ: Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8: 69-78, 2006.